Ellume USA LLC
Part of Ellume PTY LTD
- UEI
- LC8WE4G8U773
- CAGE
- 8J0W1
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Ellume PTY LTD
Parent
DG2WN7DEFB36
- Ellume USA LLC LC8WE4G8U773
-
Ellume PTY LTD
Parent
DG2WN7DEFB36
- SAM.gov registration date
- Website
- ellume.com
- Founded
- 2010
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Radx-tech - ellume USA, LLC point-of-care covid-19 antigen test for the direct detection of the sars COV-2 virus. | National Heart Lung and Blood Institute | $26,900,000 |
About Ellume USA LLC
Ellume USA LLC is a subsidiary of the Australian company Ellume PTY LTD, which is a foreign-owned, for-profit organization that develops and commercializes digital diagnostic products for clinicians and consumers. Ellume USA LLC is registered as a foreign-owned, self-certified small disadvantaged business in the System for Award Management (SAM).
Ellume USA LLC has been awarded prime federal contracts for COVID-19 diagnostic testing solutions. In September 2020, the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Heart Lung and Blood Institute awarded Ellume a $29,950,000 firm-fixed-price contract for the development of a point-of-care COVID-19 antigen test for the direct detection of the SARS-CoV-2 virus. This contract has a completion date of March 29, 2023, and does not have a set-aside designation.
Ellume USA LLC does not appear to have been directly awarded any prime federal grant funding. However, the entity has received a sub-grant award from Emory University to participate in the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) program.
In February 2021, the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Ellume USA LLC an Other Transaction (OT) Indefinite Delivery Vehicle (IDV) with a potential value of $283,858,070.93. This OT agreement, which is not subject to the Federal Acquisition Regulation (FAR), was awarded for the procurement of COVID-19 diagnostic testing prototypes. As an OT IDV, it provides the government with increased flexibility to rapidly acquire innovative technologies from Ellume USA LLC to support the national response to the COVID-19 pandemic.
Quick answers
What is Ellume USA LLC's UEI?
Ellume USA LLC's Unique Entity ID (UEI) in SAM.gov is LC8WE4G8U773.
What is Ellume USA LLC's CAGE code?
Ellume USA LLC's CAGE code is 8J0W1.
What is Ellume USA LLC's primary NAICS code?
Ellume USA LLC's primary NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing).
Is Ellume USA LLC registered in SAM.gov?
Ellume USA LLC's SAM.gov registration expired on March 28, 2024.
Who is Ellume USA LLC's parent company?
Ellume USA LLC is part of Ellume PTY LTD.
What is Ellume USA LLC's most recent federal award?
Ellume USA LLC's most recent federal contract award is Radx-tech - ellume USA, LLC point-of-care covid-19 antigen test for the direct detection of the sars COV-2 virus (75N92020C00034), from National Heart Lung and Blood Institute, on September 30, 2020.
On GovTribe
See Ellume USA LLC's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors